Evidence map›Paper›PMID 37692363›Full record

ReviewTherapeutic advances in medical oncology2023

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.

Vahid Yaghoubi Naei, Pritam Bordhan, Fatemeh Mirakhorli, Motahare Khorrami, Jesus Shrestha, Hojjatollah Nazari, Arutha Kulasinghe, Majid Ebrahimi Warkiani

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. [Progression and application of circulating tumor DNA in lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Review
  13. Article
  14. Review
  15. Liquid Biopsy: A Game Changer for Type 2 Diabetes.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Vahid Yaghoubi NaeiSchool of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
Pritam BordhanSchool of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
Fatemeh MirakhorliSchool of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
Motahare KhorramiImmunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Jesus ShresthaSchool of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.ORCID https://orcid.org/0000-0003-3692-6676
Hojjatollah NazariSchool of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
Arutha KulasingheFaculty of Medicine, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, 1, Broadway, Ultimo New South Wales 2007, Australia.
University of Technology Sydney · AUMashhad University of Medical Sciences · IRThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, the detection and analysis of liquid biopsy biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have advanced significantly. They have received recognition for their clinical usefulness in detecting cancer at an early stage, monitoring disease, and evaluating treatment response. The emergence of liquid biopsy has been a helpful development, as it offers a minimally invasive, rapid, real-time monitoring, and possible alternative to traditional tissue biopsies. In resource-limited settings, the ideal platform for liquid biopsy should not only extract more CTCs or ctDNA from a minimal sample volume but also accurately represent the molecular heterogeneity of the patient's disease. This review covers novel strategies and advancements in CTC and ctDNA-based liquid biopsy platforms, including microfluidic applications and comprehensive analysis of molecular complexity. We discuss these systems' operational principles and performance efficiencies, as well as future opportunities and challenges for their implementation in clinical settings. In addition, we emphasize the importance of integrated platforms that incorporate machine learning and artificial intelligence in accurate liquid biopsy detection systems, which can greatly improve cancer management and enable precision diagnostics.

Indexed as

cancer treatmentcirculating tumor cellscirculating tumor DNACTC characterizationctDNA characterizationmetastasismicrofluidic

Identifiers

PMID37692363
PMCPMC10486235
OpenAlexW4386497558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.